• PDK4-IN-1 Hydrochloride: Reading Metabolic Flux

  2026-09-09

  PDK4-IN-1 hydrochloride is a selective pyruvate dehydrogenase kinase 4 inhibitor for connecting PDH activation with interpretable metabolic phenotypes. This article presents an evidence-centered framework that distinguishes target engagement, mitochondrial energy metabolism modulation, and downstream flux changes in cellular and animal studies.

• WY-14643 and PPARα in Cholestatic Liver Injury

  2026-09-09

  Explore how WY-14643 (Pirinixic Acid) can be used to interrogate PPARα-driven protection against cholestatic liver injury and pyroptosis. This article translates recent mechanistic findings into assay design, formulation, and interpretation strategies.

• Polyethylenimine Linear PEI MW 40,000 Guide

  2026-09-08

  Polyethylenimine Linear, PEI MW 40,000, is a cationic DNA transfection reagent for in vitro studies. The K1029 formulation is supplied as a 2.5 mg/mL solution and is positioned for serum-compatible transient gene expression, recombinant protein production, and scalable cell-based workflows.

• Latrunculin A for Actin Dynamics: Practical Workflows

  2026-09-08

  Latrunculin A offers reversible control of actin assembly for rapid cytoskeleton disaggregation, morphology assays, and mechanobiology experiments. This workflow-focused guide shows how to connect actin perturbation with stiffness-dependent DRG axon regrowth while improving dosing, imaging, washout, and troubleshooting decisions.

• Letrozole Workflow for Aromatase Research

  2026-09-07

  Build reproducible Letrozole workflows for aromatase inhibition, estrogen receptor alpha downregulation, and endocrine-axis studies. This guide connects concentration design, orthogonal readouts, and troubleshooting with practical use cases in breast cancer research.

• Diphenyleneiodonium Chloride: Redox and cAMP Probe

  2026-09-07

  Diphenyleneiodonium chloride, or DPI, is a dual-function research compound that inhibits flavoprotein-linked redox enzymes and activates GPR3-associated cAMP signaling. Its broad enzyme activity, limited solubility, and assay-dependent behavior make controls essential in oxidative stress research.

• Doxorubicin and Nucleolar Architecture

  2026-09-05

  Doxorubicin hydrochloride is more than a cytotoxic control: it can help interrogate how DNA damage, energy stress, and nucleolar organization intersect. This article translates new 28S rRNA architecture findings into practical strategies for cancer chemotherapy research, apoptosis assays, and cardiotoxicity models.

• Uridine, Trisodium Salt in RNA Genome Engineering

  2026-09-04

  RNA-mediated genome engineering is shifting transgene delivery from DNA repair toward controlled RNA-templated synthesis. This thought-leadership analysis explains where Uridine, Trisodium Salt can support mechanistic studies, assay design, and translational decision-making around PRINT while distinguishing product utility from claims that still require validation.

• Z-VDVAD-FMK in Caspase-2 Pathway Mapping

  2026-09-04

  Z-VDVAD-FMK is an irreversible, cell-permeable probe for mapping caspase-2-linked apoptosis. This guide explains how to interpret inhibitor experiments using mitochondrial, proteolytic, and antiviral pathway readouts rather than treating caspase blockade as proof of a single mechanism.

• Canagliflozin Hemihydrate: Research Workflow Guide

  2026-09-03

  Use Canagliflozin hemihydrate as a mechanism-focused probe for SGLT2 biology and as a boundary control in mTOR inhibitor discovery. This workflow combines formulation discipline, transporter-relevant assay design, and drug-sensitized yeast to distinguish glucose-pathway activity from nonspecific TOR effects.

• Novel PDK4 Inhibitors for Metabolic Disease

  2026-09-03

  The 2019 Journal of Medicinal Chemistry study identified anthraquinone-derived allosteric inhibitors of pyruvate dehydrogenase kinase 4, with compound 8c showing nanomolar biochemical activity and efficacy in metabolic and allergic disease models. Its combination of structure–activity optimization, metabolic profiling, pharmacokinetics, docking, and in vivo testing provides a useful framework for evaluating PDK4-directed drug candidates while also highlighting the gap between promising preclinical data and clinical translation.

• HyperScribe SP6 High Yield RNA Synthesis Kit Workflow

  2026-09-02

  The HyperScribe™ SP6 High Yield RNA Synthesis Kit combines high-output SP6 transcription with flexible incorporation of capped, dye-labeled, and biotinylated nucleotides. Use it to build reproducible RNA probes, RNAi reagents, translation substrates, and mechanistic assays inspired by current SARS-CoV-2 innate-immunity research.

• AM 281: CB1 Cannabinoid Receptor Antagonist

  2026-09-02

  AM 281 is a high-affinity CB1 cannabinoid receptor antagonist for separating CB1 signaling from CB2 activity in receptor, astrocyte, neuronal survival, and cognition assays. Its strongest use-case is mechanistic neuropharmacology, where controlled CB1 inhibition can connect 2-AG signaling with CREB, GLT-1, excitotoxicity, and memory-related phenotypes.

• FK866 (APO866): NAD–PARP Precision in Cancer

  2026-09-01

  FK866 (APO866) is examined as a metabolic biomarker probe for NAD–PARP combination research, with emphasis on RAS/PI3K-mutant ovarian cancer. This article translates recent findings into assay decisions while distinguishing preclinical promise from practical limitations.

• Benzyl-activated Streptavidin Magnetic Beads

  2026-09-01

  Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301) provide magnet-assisted capture of biotinylated proteins, peptides, antibodies, sugars, lectins, oligonucleotides, and nucleic acids from complex samples. They are intended for biotin-dependent workflows and should not be treated as a general affinity reagent for non-biotinylated targets or as a substitute for application-specific validation.

7711 records 1/515 page Next 12345 下5页 Last page